相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban
Ming Zhao et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society
Diana A. Gorog et al.
EUROPACE (2022)
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases
Menglong Wang et al.
JOURNAL OF INFLAMMATION RESEARCH (2022)
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients
Innocent G. G. Asiimwe et al.
FRONTIERS IN PHARMACOLOGY (2022)
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation
Junichi Nakagawa et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021)
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
Jan Steffel et al.
EUROPACE (2021)
Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
Yan Wang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users
Jaakko Lahteenmaki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study
Ingrid Skornova et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2021)
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
Hyun Kuk Kim et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Rivaroxaban or Apixaban or Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration
Michihiro Suwa et al.
CIRCULATION JOURNAL (2019)
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
Sophie Testa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Location of cerebral atherosclerosis: Why is there a difference between East and West?
Jong S. Kim et al.
INTERNATIONAL JOURNAL OF STROKE (2018)
Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke
Shinichi Wada et al.
CIRCULATION JOURNAL (2018)
Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis
Qiufen Xie et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
Anne-Laure Sennesael et al.
THROMBOSIS JOURNAL (2018)
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
James K. Y. Hooi et al.
GASTROENTEROLOGY (2017)
Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban
Teruhiro Sakaguchi et al.
JOURNAL OF CARDIOLOGY (2017)
Factor XII Contact Activation
Clement Naudin et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2017)
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management
Ka-Shing Cheung et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: A case-control study
Naoyoshi Nagata et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
Ka Sing Lawrence Wong et al.
STROKE (2014)
Gene Expression Signatures of Coronary Heart Disease
Roby Joehanes et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
Masato Kaneko et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
The Genotype-Tissue Expression (GTEx) project
John Lonsdale et al.
NATURE GENETICS (2013)
An Updated Definition of Stroke for the 21st Century A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Ralph L. Sacco et al.
STROKE (2013)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin
Helen Mani et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran et al.
CIRCULATION (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
Ji Jiang et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype
Caroline Cheng et al.
ATHEROSCLEROSIS (2009)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
分享论文
